A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
SAFETY AND EFFICACY OF nab®-PACLITAXEL (ABRAXANE®) IN COMBINATION WITH CARBOPLATIN AS FIRST LINE TREATMENT IN ELDERLY SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE IV, RANDOMIZED, OPEN-LABEL
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma
A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease
Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant
